Advances in Small-Cell Lung Cancer: Recognizing the Potential of Immune Checkpoint Inhibitors and Antibody–Drug Conjugates

Review key data and expert commentary on new agents and where they fit into the optimal management of patients with SCLC with these downloadable slides and expert-authored module developed by Anna F. Farago MD PhD Matthew D. Hellmann MD and Taofeek K. Owonikoko MD PhD MSCR.

Share

Program Content

No activities added yet

Activities

Nivolumab ± Ipilimumab in Advanced SCLC
Immunotherapy: An Intriguing Work in Progress for the Treatment of Advanced SCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Bristol Myers Squibb